Posted on

The Trip of a Lifetime

DOSED 2 Screening with Dr. Gabor Maté & Dennis McKenna Q&A

Mark your calendar – DOSED 2: The Trip of a Lifetime is coming to the Vogue Theatre in Vancouver on  August 3rd! 

If you haven’t seen the original DOSED, check it out here. The award-winning documentary follows a woman overcoming opioid addiction with psilocybin and iboga.

DOSED 2 shares the remarkable story of a terminally-ill cancer patient who was granted the right to try psilocybin mushrooms to treat her end of life anxiety.

The special event premiere screening will be followed by an audience Q&A with:

  • Renowned addiction expert and author Dr. Gabor Maté
  • Legendary psychonaut Dennis McKenna
  • Psychedelic therapist (and your fave Daily Mushroom Podcast guest) Dave Phillips
  • Patient Laurie Brooks
  • Filmmakers Tyler Chandler & Nicholas Meyers
  • And more!

Get screening tickets

Watch the DOSED 2 trailer

Posted on

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

Psilocybin reduced reinstatement of heroin-seeking behavior when administered immediately after a memory retrieval task in rats

Vancouver, British Columbia–(Newsfile Corp. – June 2, 2022) – Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the “Company”), a Canadian-based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction treatment and ongoing pain management, in conjunction with Integrative Therapy Discovery (ITD) Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin-addicted brain.

The study was carried out by Dr. Massimo Nabissi from the School of Pharmacy Section of Experimental Medicine, University of Camerino in Camerino, Italy. The preclinical study evaluated the effect of psilocybin on in-vitro rat brain cell line models and an in-vivo rat model on heroin self-administration and reinstatement of heroin seeking behavior following memory retrieval tests. Drug self-administration is regarded as a gold-standard preclinical model of addiction and substance-use disorders. The aim of the project was threefold and are as follows.

  • To evaluate the effect of psilocybin in modulating heroin molecular pathways in in vitro rat brain cell line models
  • To evaluate the effect of psilocybin on heroin self-administration (in vivo results)
  • To evaluate the effect of psilocybin on reinstatement of heroin seeking following memory retrieval test (in vivo results)

Gene Analysis was performed by the Clariom S Assay tool. This machine serves as a next generation transcriptome-wide gene-level expression profiling tool, which allows for the fastest, simplest and most scalable path to generating actionable results. Based on industry-leading microarray technology, the novel rat Clariom S Assay provides extensive coverage of all known well-annotated genes, compatibility with clinical sample types, scalable formats, and flexible data analysis software. The GeneChip™ Rat Genome 230 2.0 Assay was used to evaluate gene expression levels and in cell lines that were treated with heroin and psilocybin and with psilocybin in combination with heroin.

The immortalized rat hypothalamus cells (RCHT-1) were derived from the hypothalamus of a four-month-old Fisher Rat. The hippocampal cells (H19-7) derived from the rats’ hippocampi were treated daily with heroin and psilocybin, alone or in combination. After 48 hours, cell lines were collected for RNA extraction and gene array analysis. For each of the comparisons indicated, an electronic file was created that includes differentially expressed transcripts that were identified in both H19-7 and RCTH-1 cells with extended annotations. A second file was created that made comparisons evidencing only the transcript differences where the Ct (or cell type) value was highly different as a final analysis. For each of these data sets, only the genes whose expression was reverted by psilocybin and in the treatments consisting of heroin plus psilocybin were selected. Moreover, only the genes whose expression was psilocybin dose dependent were considered. In summary, the potential candidate genes whose expression in heroin treatment was reverted by psilocybin and evidenced in the electronic file reports were selected.

The effect of heroin and psilocybin in reducing cell viability was evaluated in HT19-7 and RCHT-1 cell lines by daily administration. Cells were treated for 48 hours with either heroin or psilocybin or with a combination of heroin with psilocybin and then were analyzed. The percentage of cell viability was evaluated by a cell viability assay whose results showed a dose-dependent heroin effect in the RCHT-1 cell line with specific IC50 values. While in HT19-7 cell lines, no cytotoxic effects were observed at the concentrations used. Regarding psilocybin, similar results were obtained in cell lines with specific IC50 values and with both RCHT-1 and HT19-7 cell lines. To gain further insight, heroin was combined with psilocybin at varying doses to evaluate the optimal combination for transcriptional study. The results showed that when used together at varying dosages, the combinations were not cytotoxic in either of the two cell lines.

The study goes on to show how treatment with psilocybin effected self-administered heroin use via lever presses along with the overall effect that psilocybin combined with heroin had on certain behavioral models in both male and female Wistar rat populations. A preliminary experiment aimed at testing the efficacy of psilocybin to prevent heroin relapse following cue memory reconsolidation was also conducted. Altogether, these results suggest that psilocybin decreased reinstatement of heroin seeking in female rats. As a final analysis, the gene data evidenced in the study was subjected to a comprehensive academic wide search of available current littérature and, although information regarding a correlation with psilocybin and opioid addiction was available, a transcriptome analysis for heroin and psilocybin and their co-combination has never been previously investigated. As a result, the data presented in this study can be extremely useful for determining a better understanding of dependent doses and the molecular mechanisms involved in the potential modulation of heroin (or opioids in general) addiction and dependence.

In summary, the information contained within the study dealing with relapse prevention is new and groundbreaking evidence in the field of pharmaceutical addictions medicine and chemotherapy. This type of comprehensive study, which constitutes concrete scientific evidence-based data, is at the heart of Nirvana Life Sciences’ business objective which is to develop and seek FDA approval for therapeutic formulations and novel pharmaceuticals.

Dr. Sazzad Hossain, CSO of Nirvana, states, “Our research team has over 100 years of combined academic and applied experience in the field of psychedelic science. I’m excited to see what they can do with this new information.”

About Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. has been founded with a simple objective of researching and developing non-addictive pain management and relapse prevention products that can provide healthier outcomes for patients who live with chronic pain and/or have battled with addiction. Nirvana believes that using naturally sourced psychedelics in novel formulations holds the promise of delivering non-addictive solutions that are effective in managing pain and addiction. Nirvana’s team, consisting of leading researchers from around the globe, will develop therapies that have the potential of freeing millions from addiction and saving society billions of dollars annually.

For further information:

Bruce Clark- CEO
info@nirvanalifescience.com
Phone: 604-401-8100

Forward-Looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward- looking statements”) within the meaning of Canadian securities laws including, without limitation, statements with respect to the future investments by the Company. All statements other than statements of historical fact are forward-looking statements. Undue reliance should not be placed on forward-looking statements, which are inherently uncertain, are based on estimates and assumptions, and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by the forward-looking statements will not occur. Although the Company believes that the expectations reflected in the forward-looking statements contained in this press release, and the assumptions on which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements included in this document, as there can be no assurance that the plans, intentions or expectations upon which the forward-looking statements are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause the Company’s actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, except as required by applicable law. The forward-looking statements contained herein are expressly qualified by this cautionary statement.

Posted on

30% less opioid use

Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

A recent survey of 200,000+ people found that those who have used psilocybin at least once are 30% less likely to have opioid use disorder. However, LSD, mescaline, and peyote use did not seem to have an impact on opioid use. Addiction is linked with abnormal serotonin neurotransmission. Since psilocybin targets the serotonin system, it may help protect against opioid addiction.

Learn more with Chloe Deutscher on TikTok

PDF of article

Posted on

Detox with Indigenous wisdom

Universal Ibogaine and Osoyoos Indian Band sign MOU to battle opioid crisis

Universal Ibogaine (IBO) and Osoyoos Indian Band signed an agreement to develop a detox center that combines western science and Indigenous wisdom.

The center will use ibogaine treatments to ease opioid cravings and withdrawal symptoms, followed by Indigenous healing practices as aftercare to “rebuild people in a holistic manner.”

Their flagship detox center will be in Manitoba, Canada with the goal of working with other First Nations to expand across the country, and then globally. 

Posted on

Universal Ibogaine Commences Development Plan At Kelburn In Preparation For Ibogaine Treatments And Provides Update On Drug Supply

Universal Ibogaine Commences Development Plan At Kelburn In Preparation For Ibogaine Treatments And Provides Update On Drug Supply

CALGARY, AB, Feb. 2, 2022 /CNW/ – Universal Ibogaine Inc. (TSXV: IBO) (“UI” or the “Company“) a life sciences company with a mission to deliver medicalized ibogaine-centered addiction treatment, has initiated development plans at its Kelburn treatment facility in preparation for treatment protocol approval and commencement of ibogaine treatments.

What is Ibogaine?

Ibogaine is a plant derived neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state.  Ibogaine has demonstrated particular effectiveness in treating opioid use disorder.  When applied according to a strict safety protocol, ibogaine appears to eliminate the most painful symptoms of opioid withdrawal and provides a several month window free of drug cravings.  Dr Alberto Sola, co-founder of Universal Ibogaine has administered more ibogaine treatments than any other doctor in the world. 

Kelburn Addiction Treatment Center

Universal Ibogaine acquired the licensed and operational Kelburn Mental Health and Addiction Treatment facility in October of 2021.  The facility sits on a destination 50 acre estate with a 9 hole golf course and currently operates as a traditional addiction treatment center. 

Universal Ibogaine has undertaken plans to expand the facility to include traditional drug detox and to begin to incorporate the best in nuovo treatment modalities including Ketamine, Psilocybin and MDMA assisted psychotherapies. 

Universal Ibogaine has commenced development plans to construct a stand alone ibogaine detox facility on the property in preparation for the completion of its proof of concept study with Health Canada.


Dr Ian Rabb – Chief Clinics Officer

Dr Ian Rabb of Universal Ibogaine stated: “In my 20 years of addiction treatment, I have not seen anything with the power and promise of ibogaine to break the cycle of addiction.  When paired with a long term support plan, which we provide through our Kelburn facility, we expect to completely disrupt the addiction treatment model.  Ibogaine is legal in Canada under the prescription drug list and requires a proof of safety trial through Health Canada.  We are sitting on the edge of being able to tackle the opioid crisis head on.”

Drug Supply Update

Universal Ibogaine would also like to provide an update regarding the drug supply agreement with Psygen. The agreement was announced prematurely and contained some minor errors regarding the synthesis of the compound.  As a result, the parties to the agreement have withdrawn.

UI is currently in negotiations with two alternative drug suppliers.


About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, when paired with the ibogaine detox protocol, is intended to
revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS


‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI. Although UI believes that the expectations
and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.


Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎


For further information:


Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com


Media Contact: Cathy Fernandes, Director – Marketing & Communications
cathy.fernandes@universalibogaine.com

Posted on

Universal Ibogaine Enters Drug Supply Agreement

Universal Ibogaine Enters Drug Supply Agreement

Calgary, AB – January 26, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to advise it has entered into an agreement (the “agreement”) with Psygen Labs Inc. (“Psygen”) to secure a supply of GMP ibogaine for use in its planned future clinical trial for opioid use disorder and ongoing ibogaine detox treatments at its clinics.


UI is in process of finalizing its pre-clinical trial (“pre-CTA”) submission to Health Canada, following which it intends to apply to undertake a clinical trial of ibogaine for use in treatment of opioid use disorder(s). The final approval by Health Canada will require UI to have an approved, secure supply of GMP certified ibogaine to use in the eventual clinical trial process. Psygen is a Canadian company based in Calgary and is a leader in the manufacture of a range of medical grade products being used in the emerging
psychedelics-based psycho-therapy field of treatment of anxiety, depression and other mental health issues.


Nick Karos – Universal Ibogaine CEO
Nick Karos noted “We are pleased to have secured a firm of Psygen’s caliber as one of our key partners.Ibogaine has been used in tribal ceremonies in Africa for centuries and has traditionally been sourced for medical use from the root bark of a shrub found in limited areas of the Congo basin in Africa. Psygen has developed a process to manufacture synthetic ibogaine, which will provide a more secure and sustainable source of supply for our trials and a scalable solution for our treatment protocol to help as many people as possible. We look forward to a long-term partnership with Psygen as part of our goal of having ibogaine
approved for wide-scale use in opioid detoxification and addiction treatments.”


About Universal Ibogaine Inc.
UI is a life sciences company, with a mission to demonstrate the safety and efficacy of its ibogaine based drug detox protocol through a Canadian Clinical Trial, and ultimately to utilize that protocol around the globe through future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Clinic that, when paired with the ibogaine detox protocol, is intended to
revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS


‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur. The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI. Although UI believes that the expectations
and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.


Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect
and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof. UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎


For further information:

Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com

Media Contact: Cathy Fernandes, Director – Marketing & Communications
cathy.fernandes@universalibogaine.com

Posted on

Universal Ibogaine Announces World-class Clinical Trial Partners In Advance Of Clinical Trial Application For Ibogaine In Opioid Use Disorder

Universal Ibogaine Announces World-class Clinical Trial Partners In Advance Of Clinical Trial Application For Ibogaine In Opioid Use Disorder

Calgary, AB – January 14, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to introduce its contract research organization (“CRO”) partners who will enable UI’s planned clinical trial in Canada to be conducted, subject to the required approval by Health Canada. UI is currently working with its CRO partners to finalize UI’s study design in advance of an anticipated pre-clinical trial application meeting to soon be held with Health Canada.

UI has selected Intrinsik Corp. (“Intrinsik”), an internationally recognized regulatory affairs consulting firm, to provide regulatory strategy and support for the preparation and submission of UI’s Canadian Clinical Trial Application (“CTA”), as well as follow-up and monitoring if a No Objection Letter (“NOL”) is received from Health Canada. Intrinsik is comprised of an experienced team who have driven hundreds of successful clinical trials and investigational new drug applications and have collectively contributed to more than 20 new drug marketing applications. The group has over 25 regulatory affairs professionals based in its Canadian headquarters located in the greater Toronto area, and unparalleled expertise and experience related to Central Nervous System Disorders (CNS: the therapeutic area to which addiction and mental health disorders belong). 

Support for the development of the substance of the CTA package, as well as ultimately the operation of the clinical trial itself, is being provided by the world-class team at CATO Research Canada Inc.(“CATO SMS”). The CATO SMS team of experts have over 30-years’ experience optimizing the design and execution of clinical trials for life sciences companies such as UI. CATO SMS has successfully conducted over 500 clinical trials in over 25 countries and have enrolled more than 60,000 patients at over 5,500 sites. 

The CATO SMS engagement team, along with UI’s team, involves a variety of experts in Canada, the US and Europe, providing critical expertise ranging from clinical study designs to biostatistics to clinical operations (e.g., patient recruitment, study startup, budgeting, site management, data management, etc.). CATO SMS’ contributions will also include the analysis and synthesis of proprietary real-world data and evidence ( “RWD” and “RWE”, respectively) stemming from the application of ibogaine for the treatment of opioid use disorder in approximately 200 patients who have been treated in Cancun, Mexico by UI’s licensing partner – Clear Sky Recovery Cancun SA de CV.  UI believes that the presentation of RWD and RWE as part of the CTA package will strengthen the application, particularly the preliminary claim to safety, and is aligned with emerging guidance by regulators, such as the US Food and Drug Administration (“FDA”), to acknowledge and incorporate RWD and RWE in clinical development, and generally in evidence-based medicine.    

Finally, UI is lining up prominent academic and medical centres to support the CTA to Health Canada, as well as potentially serve as sites to undertake the ultimate clinical trial. Notably, UI has engaged the research office of a leading Canada-based academic and teaching institution in the therapeutic area of addiction to support the design of the study protocol and generate interest in trial site selection.

Nick Karos – Universal Ibogaine CEO

Nick Karos (CEO) noted “Our engagement with Health Canada to date has clearly highlighted the road UI must take to provide practitioners and patients access to authorized ibogaine in Canada to treat opioid use disorder. The conduct of clinical trials is a very precise business requiring solid partnerships with the right expertise and players, and Universal Ibogaine is pleased that we have now secured these partnerships. We are confident that that with our partners expertise, we will move towards our goal of conducting clinical trials with Health Canada.”

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to develop and acquire a network of addiction treatment clinics throughout Canada, and to eventually use ibogaine as a primary modality for the interruption and ideally cessation of addictions: primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants.  

As such, UI concurrently plans to clinically develop ibogaine, a plant derived substance, as an authorized addiction interruption medicine for the treatment of Opioid Use Disorder.  A Clinical Trial Application to Health Canada is being developed to undertake clinical trials in Canada, aimed at proving the safety and efficacy of the use of ibogaine for this purpose.  In the longer term, and once approved as planned, UI will introduce ibogaine into the addiction treatment protocols to be used in its future facilities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS 

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as “plans”, “expect”, “project”, “intend”, “will”, “believe”, “anticipate”, “estimate”, “scheduled”, ‎‎”potential”, or other similar words, or statements that certain events or conditions “may”, “should” or ‎‎”could” occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI.  Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct. 

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

For further information: 

Investor Relations: Dugan Selkirk, IR Manager

dugan.selkirk@universalibogaine.com

Media Contact: Cathy Fernandes, Director – Marketing & Communications cathy.fernandes@universalibogaine.com 

Posted on

Could this African shrub solve the opioid crisis?

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? 🤔

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

PDF of article

Posted on

US government studies ibogaine

Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Hallucinogenic Therapies to Treat Substance Use Disorders

Delix Therapeutics, a private Boston-based company, is partnering with The National Institute on Drug Abuse (NIDA) to develop a treatment for substance abuse. The partnership will evaluate Delix’s non-hallucinogenic formulation of ibogaine, which has already shown promise of reducing alcohol- and heroin-seeking behavior.

PDF of article